Bod Australia hits major milestone in cannabis wafer trial

Bod Australia ASX BDA CBD trial cannabidiol ECs315 cannabis extract clinical trial
Bod Australia has shown that CBD can be delivered into a patient’s bloodstream using its patented wafer during its phase one clinical trial.

Cosmetics and natural medicines company Bod Australia (ASX: BDA) has achieved what it calls a “world-first” in the clinical trial of its proprietary phytocomplex cannabis extract ECs315, showing that cannabidiol (CBD) can be delivered into a patient’s bloodstream using its patented wafer system.

The company launched the phase one clinical trial in July, aiming to test the safety, tolerability and pharmacokinetics (how a drug is absorbed, distributed, metabolised and excreted in

... read more at: https://smallcaps.com.au/bod-australia-milestone-cannabis-wafer-trial/

by